Analyst Price Targets — VYGR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2025 10:33 am | Yanan Zhu | Wells Fargo | $10.00 | $3.81 | TheFly | Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo |
| November 13, 2024 3:53 pm | Jay Olson | Oppenheimer | $18.00 | $6.92 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Voyager Therapeutics (VYGR) |
| September 25, 2024 6:53 am | Jack Allen | Robert W. Baird | $18.00 | $6.04 | StreetInsider | Baird Reiterates Outperform Rating on Voyager Therapeutics (VYGR) |
| May 14, 2024 6:47 am | Laura Chico | Wedbush | $8.00 | $8.48 | StreetInsider | Voyager Therapeutics (VYGR) PT Lowered to $8 at Wedbush |
| January 2, 2024 1:08 pm | Jim Birchenough | Wells Fargo | $14.00 | $9.00 | StreetInsider | Wells Fargo Upgrades Voyager Therapeutics (VYGR) to Overweight |
| May 10, 2023 3:18 pm | Joon Lee | Truist Financial | $18.00 | $9.88 | Benzinga | Voyager Therapeutics' Seasoned Management And Leading Adeno-Associated Virus Capsid Platform Impress Bullish Analyst |
Latest News for VYGR
Longeveron (NASDAQ: LGVN - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability. Risk and Volatility Longeveron has a beta of
Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients. Company's robust cash position, projected to fund operations into 2028, is further…
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.59 per share a year ago.
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended 2025 with cash position of $202 million, expected to maintain…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VYGR.
U.S. House Trading
No House trades found for VYGR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.